Jun 2026 (Q2 FY26) — Jul 30, 2026
Ingevity Q2 FY26 — Strong Performance, Raised Outlook, and Portfolio Transformation Progress
Read the full callIngevity (NGVT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Ingevity earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 314 | −5.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 35.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$70.31 +0.70% · +$0.49
Performance +29.4% 1Y
1Y: $54.32 on 17 Oct 2025 → $70.31. High $77.87 (6 May 2026), low $46.2 (6 Nov 2025).
- Previous close
- $69.82
- 52-week range
- $46.2 – $77.87
- One year
- +25.15%
Overview
- Symbol
- NGVT
- Sector
- Materials
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Ingevity earnings calls (NGVT)
Financials
What the filings say
Net profit, year on year: +124% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 334 | 299 | 248 | 332 | 333 | 255 | 258 | 314 |
| Operating profit | 110 | 81 | — | — | — | — | — | — |
| Operating margin | 33.0% | 27.0% | — | — | — | — | — | — |
| Profit before tax | 54 | 9 | 38 | -137 | 62 | -105 | 30 | 51 |
| Tax rate | 12.0% | −88.6% | 22.6% | −3.5% | 34.4% | 25.2% | 22.5% | 21.5% |
| Net profit | -107 | 17 | 21 | -146 | 44 | -85 | 60 | 35 |
| EPS ($ per share) | -2.95 | — | 0.56 | -4.02 | 1.20 | — | 1.70 | 1.02 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 314 | 497 | 678 | 796 | 1,008 | 1,002 | 572 | 405 |
| Total liabilities | 977 | 1,611 | 1,692 | 1,795 | 2,038 | 1,992 | 1,827 | 1,621 |
| Fixed assets | 524 | 665 | 704 | 720 | 799 | 762 | 643 | 608 |
| Total assets | 1,315 | 2,142 | 2,335 | 2,469 | 2,737 | 2,623 | 2,023 | 1,651 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 252 | 276 | 352 | 293 | 313 | 205 | 129 | 331 |
| Cash from investing | -414 | -658 | -111 | -139 | -552 | -77 | -79 | -57 |
| Cash from financing | 154 | 369 | -50 | -133 | 48 | -100 | -70 | -252 |
| Net cash flow | -10 | -13 | 194 | 20 | -196 | 28 | -25 | 26 |
| Capital expenditure | -94 | -115 | -82 | -104 | -142 | -110 | -78 | -58 |
| Free cash flow | 158 | 161 | 270 | 190 | 171 | 95 | 51 | 274 |
Insider filings
72 filings between Jan 2, 2026 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.76M
10 sales by 3 insiders
50% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 31
- Award — granted as compensation
- 31
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Li David H | — | $1.53M | Aug 18, 2026 |
| Fisher Ryan C. | — | $199.7K | Aug 3, 2026 |
| DYER TERRANCE M | — | $34.0K | May 28, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Segal Francis David Director | Award | 335 | $23.8K |
| Oct 1, 2026 | WILLIS J KEVIN Director | Award | 405 | $28.8K |
| Aug 18, 2026 | Li David H President & CEO | Sale 10b5-1 plan | 92 | $6.9K |
| Aug 17, 2026 | Li David H President & CEO | Sale 10b5-1 plan | 5,000 | $379.1K |
| Aug 14, 2026 | Li David H President & CEO | Sale 10b5-1 plan | 5,000 | $378.6K |
| Aug 13, 2026 | Li David H President & CEO | Sale 10b5-1 plan | 5,000 | $378.6K |
| Aug 12, 2026 | Li David H President & CEO | Sale 10b5-1 plan | 5,000 | $383.1K |
| Aug 10, 2026 | PLATT PHILLIP JOHN SVP, Chief Financial Officer | Tax withheld | 1,698 | $130.8K |
| Aug 3, 2026 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Sale | 1,397 | $103.0K |
| Aug 3, 2026 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Sale | 1,312 | $96.7K |
| Jul 24, 2026 | PLATT PHILLIP JOHN SVP, Chief Financial Officer | Tax withheld | 3,294 | $241.3K |
| Jul 6, 2026 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Tax withheld | 168 | $12.4K |
| Jul 1, 2026 | WILLIS J KEVIN Director | Award | 397 | $28.8K |
| Jul 1, 2026 | Segal Francis David Director | Award | 328 | $23.8K |
| Jun 22, 2026 | Cotterman Ryan Joseph VP, Chief Accounting Officer | Award | 2,063 | $0 |
| May 28, 2026 | DYER TERRANCE M SVP, Chief HR Officer | Sale | 30 | $2.1K |
| May 28, 2026 | DYER TERRANCE M SVP, Chief HR Officer | Sale | 200 | $13.7K |
| May 28, 2026 | DYER TERRANCE M SVP, Chief HR Officer | Sale | 266 | $18.2K |
| May 1, 2026 | PLATT PHILLIP JOHN SVP, Finance & CAO | Award | 1,262 | $0 |
| Apr 30, 2026 | Segal Francis David Director | Award | 1,904 | $0 |
| Apr 30, 2026 | Wright Benjamin G. Director | Award | 1,904 | $0 |
| Apr 30, 2026 | NARWOLD KAREN G Director | Award | 1,904 | $0 |
| Apr 30, 2026 | Lynch Frederick J Director | Award | 1,904 | $0 |
| Apr 30, 2026 | WILLIS J KEVIN Director | Award | 1,904 | $0 |
| Apr 30, 2026 | FERNANDEZ-MORENO LUIS M Director | Award | 1,904 | $0 |
| Apr 30, 2026 | Hoechner Bruce D. Director | Award | 1,904 | $0 |
| Apr 30, 2026 | Gulyas Diane H. Director | Award | 1,904 | $0 |
| Apr 7, 2026 | Li David H President & CEO | Tax withheld | 13,102 | $924.6K |
| Apr 7, 2026 | Li David H President & CEO | Tax withheld | 3,574 | $252.2K |
| Apr 1, 2026 | Segal Francis David Director | Award | 329 | $23.8K |
| Apr 1, 2026 | WILLIS J KEVIN Director | Award | 398 | $28.8K |
| Mar 25, 2026 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Tax withheld | 308 | $22.1K |
| Mar 2, 2026 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Tax withheld | 103 | $7.4K |
| Mar 2, 2026 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Tax withheld | 355 | $25.4K |
| Mar 2, 2026 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Tax withheld | 195 | $14.0K |
| Mar 2, 2026 | White Richard Allen JR SVP and Pres, Perf Chemicals | Tax withheld | 617 | $44.2K |
| Mar 2, 2026 | White Richard Allen JR SVP and Pres, Perf Chemicals | Tax withheld | 217 | $15.5K |
| Mar 2, 2026 | PLATT PHILLIP JOHN SVP, Finance & CAO | Tax withheld | 407 | $29.2K |
| Mar 2, 2026 | White Richard Allen JR SVP and Pres, Perf Chemicals | Tax withheld | 351 | $25.1K |
| Mar 2, 2026 | PLATT PHILLIP JOHN SVP, Finance & CAO | Tax withheld | 340 | $24.4K |
| Mar 2, 2026 | PLATT PHILLIP JOHN SVP, Finance & CAO | Tax withheld | 99 | $7.1K |
| Mar 2, 2026 | Clontz Clarence Reid Jr. SVP, Operations | Tax withheld | 143 | $10.2K |
| Mar 2, 2026 | PLATT PHILLIP JOHN SVP, Finance & CAO | Tax withheld | 224 | $16.0K |
| Mar 2, 2026 | Hall Mary Dean EVP, Chief Financial Officer | Tax withheld | 559 | $40.0K |
| Mar 2, 2026 | Hall Mary Dean EVP, Chief Financial Officer | Tax withheld | 1,679 | $120.3K |
| Mar 2, 2026 | White Richard Allen JR SVP and Pres, Perf Chemicals | Tax withheld | 755 | $54.1K |
| Mar 2, 2026 | DYER TERRANCE M SVP, Chief HR Officer | Tax withheld | 550 | $39.4K |
| Mar 2, 2026 | Hall Mary Dean EVP, Chief Financial Officer | Tax withheld | 1,363 | $97.6K |
| Mar 2, 2026 | Hall Mary Dean EVP, Chief Financial Officer | Tax withheld | 747 | $53.5K |
| Mar 2, 2026 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Tax withheld | 680 | $48.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Ingevity Corp
Free account. Everything above stays public.
Write why you follow Ingevity Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading